Mike Lytle, Dave Decker to Lead Sales at Intrinsic Therapeutics

Intrinsic Therapeutics Inc. has appointed industry veterans Mike Lytle and Dave Decker as sales vice presidents for the U.S. West and East, respectively. Together, the pair have more than 60 years of combined experience in spine and orthopedics, along with decades of trusted relationships with surgeons and spinal product distributors.

“Mike and Dave are proven leaders and successful team builders, each with a track record of driving sales growth across multiple high-performing spine implant companies,” Intrinsic Therapeutics President/CEO Keith Valentine said. “Their appointment marks an important step forward in our mission to end needless suffering for high-risk discectomy patients. Having worked alongside them for nearly two decades, I know firsthand their professionalism, integrity, and ability to deliver results through a culture of accountability. With their leadership, we are poised to reach more patients, empower more surgeons, and make our vision a reality.”

Decker has more than 30 years of experience in spine and orthopedics. Most recently, he was an associate vice president at SeaSpine/Orthofix, where his area ranked as a top-performing region for three consecutive years. Previously, he spent 11 years as area sales director at NuVasive Inc., where he was repeatedly recognized as a top area leader.

“Barricaid represents a major advancement in the treatment of disc herniation, enabling us to meet patient needs like never before,” Decker stated. “By redefining the standard of care, we can transform the lives of countless patients affected by this condition.”

Lytle has more than 30 years of medical device experience, including 17 years in spine. He spent over a decade as associate vice president at Orthofix/SeaSpine, leading one of the company’s top-producing regions five times. Before that, he was senior sales director at NuVasive for six years, earning multiple Chairman’s Club awards.

“Having personally experienced complications from a failed multilevel discectomy, I am deeply passionate about Intrinsic’s mission,” Lytle remarked. “Alongside our surgeon partners, we have an obligation to ensure that every qualified patient has access to Barricaid so they can avoid the challenges I faced and live healthier lives.”

Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects after lumbar discectomy surgery. Barricaid has been implanted in more than 12,000 patients and is supported by clinical studies across eight distinct patient populations, including two randomized controlled trials and six single-arm studies. Clinical data show Barricaid reduces the risk of reoperation for reherniation by 81%,* and a multi-center Level I RCT demonstrating superior outcomes to discectomy alone was published in JAMA with five-year follow-up results.

Intrinsic Therapeutics is a medical technology company aiming to redefine the care standard for lumbar discectomy patients with large annular defects.

* Some studies are outside U.S. Food and Drug Administration indications. Values at a minimum of one-year post-op. Minimum study size: 20 Barricaid subjects.